WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596676
Description: L 734217 is a fibrinogen receptor antagonist.
MedKoo Cat#: 596676
Name: L 734217
Chemical Formula: C18H31N3O4
Exact Mass: 353.2315
Molecular Weight: 353.46
Elemental Analysis: C, 61.17; H, 8.84; N, 11.89; O, 18.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L 734217; L-734217; L734217; L-734,217; L 734,217; L734,217;
IUPAC/Chemical Name: (R)-3-(2-((R)-2-oxo-3-(2-(piperidin-4-yl)ethyl)piperidin-1-yl)acetamido)butanoic acid
InChi Key: SFFMYDBKYYBJRY-HIFRSBDPSA-N
InChi Code: InChI=1S/C18H31N3O4/c1-13(11-17(23)24)20-16(22)12-21-10-2-3-15(18(21)25)5-4-14-6-8-19-9-7-14/h13-15,19H,2-12H2,1H3,(H,20,22)(H,23,24)/t13-,15+/m1/s1
SMILES Code: C[C@@H](NC(CN1C([C@H](CCC2CCNCC2)CCC1)=O)=O)CC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 353.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999 Jul 15;94(2):587-99. PubMed PMID: 10397726.
2: Prueksaritanont T, Stranieri MT, Hand EL, Ellis JD, Holahan MA, Sitko GR, Cook JJ. Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734,217, in dogs. Biopharm Drug Dispos. 1997 Nov;18(8):649-63. PubMed PMID: 9373723.
3: Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF 3rd, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73. PubMed PMID: 8764336.
4: Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang CT, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, et al. Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J Med Chem. 1995 Aug 18;38(17):3332-41. PubMed PMID: 7650686.